Breaking News Instant updates and real-time market news.

CRBP

Corbus Pharmaceuticals

$8.25

0.45 (5.77%)

07:38
11/29/16
11/29
07:38
11/29/16
07:38

Corbus commencing one-year open-label extension to Resunab phase 2 study

Corbus Pharmaceuticals announced that it is commencing a one-year, open-label extension study of the ongoing Phase 2 clinical study of Resunab, JBT-101, for the treatment of skin-predominant dermatomyositis. This open-label extension was submitted to and reviewed by the U.S. FDA. The goal of the open-label extension dermatomyositis study is to provide all enrolled subjects with the option of receiving JBT-101 for one year after they complete the four-month, double-blind placebo controlled portion of the study and to collect long-term safety and efficacy on JBT-101. The safety and efficacy endpoints used in the double-blinded, placebo-controlled portion of the study will be assessed throughout the one year extension study. The Phase 2 study in skin-predominant dermatomyositis is funded by a grant from the National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health to the University of Pennsylvania School of Medicine.

CRBP Corbus Pharmaceuticals
$8.25

0.45 (5.77%)

09/19/16
AGIS
09/19/16
NO CHANGE
Target $12
AGIS
Buy
Corbus Pharmaceuticals price target raised to $12 from $7 at Aegis
Aegis analyst Robert Leboyer raised his price target for Corbus Pharmaceuticals to $12 from $7 and keeps a Buy rating on the name.
10/04/16
CANT
10/04/16
INITIATION
Target $17
CANT
Buy
Corbus Pharmaceuticals initiated with a Buy at Cantor
Cantor initiated Corbus Pharmaceuticals with a Buy and a $17 price target.
10/25/16
NBLE
10/25/16
NO CHANGE
NBLE
Corbus Pharmaceuticals risk/reward remains favorable, says Noble Financial
Noble Financial analyst Kumaraguru Raja remains bullish on Corbus' Resunab being developed for treating inflammation and fibrosis as it preferentially targets CB2 receptor; saying preliminary positive data in healthy volunteers validates role in inflammation resolution. The analyst said Resunab has better anti-inflammatory activity even in low doses adn the open-label extension indicates the FDA comfort with safety and efficacy. Raja likes Corbus' risk/reward heading into multiple data readouts and reiterates his Buy rating and $19 price target on shares.
11/15/16
JMPS
11/15/16
NO CHANGE
JMPS
Corbus Pharmaceuticals price target raised to $20 from $9 at JMP Securities
JMP Securities analyst Liisa Bayko raised her price target on Corbus as she believes that data on the company's Resunab drug for scleroderma indicates that its efficacy could be significantly positive, while its safety/tolerability could be "favorable." Bayko keeps an Outperform rating on the shares.

TODAY'S FREE FLY STORIES

LCNB

LCNB Corp.

$22.60

-0.7 (-3.00%)

08:41
02/27/17
02/27
08:41
02/27/17
08:41
Initiation
LCNB Corp. initiated  »

LCNB Corp. initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ETSY

Etsy

$12.72

0.21 (1.68%)

, SHOP

Shopify

$61.75

-0.98 (-1.56%)

08:40
02/27/17
02/27
08:40
02/27/17
08:40
Recommendations
Etsy, Shopify, Stamps.com analyst commentary  »

Several data points…

ETSY

Etsy

$12.72

0.21 (1.68%)

SHOP

Shopify

$61.75

-0.98 (-1.56%)

STMP

Stamps.com

$131.60

-2.15 (-1.61%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 27

    Feb

  • 28

    Feb

08:40
02/27/17
02/27
08:40
02/27/17
08:40
General news
U.S. durable goods orders rebounded 1.8% in January »

U.S. durable goods orders…

ERIC

Ericsson

$6.45

-0.08 (-1.23%)

, QCOM

Qualcomm

$57.22

0.08 (0.14%)

08:39
02/27/17
02/27
08:39
02/27/17
08:39
Conference/Events
Drexel Hamilton Events at Mobile World Congress »

Meetings with various…

ERIC

Ericsson

$6.45

-0.08 (-1.23%)

QCOM

Qualcomm

$57.22

0.08 (0.14%)

CSCO

Cisco

$34.32

0.28 (0.82%)

SNCR

Synchronoss

$30.49

-0.37 (-1.20%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 27

    Feb

  • 27

    Feb

  • 27

    Feb

  • 28

    Feb

  • 03

    Mar

  • 13

    Mar

  • 29

    Mar

REGN

Regeneron

$361.01

0.05 (0.01%)

, SNY

Sanofi

$42.70

0.19 (0.45%)

08:39
02/27/17
02/27
08:39
02/27/17
08:39
Hot Stocks
Regeneron, Sanofi to present new data on DUPIXENT at AAD »

Regeneron Pharmaceuticals…

REGN

Regeneron

$361.01

0.05 (0.01%)

SNY

Sanofi

$42.70

0.19 (0.45%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Mar

  • 09

    Mar

  • 17

    Mar

  • 29

    Mar

LAUR

Laureate Education

$13.24

0.06 (0.46%)

08:38
02/27/17
02/27
08:38
02/27/17
08:38
Initiation
Laureate Education initiated  »

Laureate Education…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INVH

Invitation Homes

$21.60

0.02 (0.09%)

08:37
02/27/17
02/27
08:37
02/27/17
08:37
Initiation
Invitation Homes initiated  »

Invitation Homes…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FNB

F.N.B.

$15.65

-0.02 (-0.13%)

, YDKN

Yadkin Financial

$33.42

-0.14 (-0.42%)

08:37
02/27/17
02/27
08:37
02/27/17
08:37
Hot Stocks
F.N.B. receives final regulatory approvals for proposed merger of Yadkin Financial »

F.N.B. (FNB) announced…

FNB

F.N.B.

$15.65

-0.02 (-0.13%)

YDKN

Yadkin Financial

$33.42

-0.14 (-0.42%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ENB

Enbridge

$41.34

-0.37 (-0.89%)

, SE

Spectra Energy

$40.68

-0.32 (-0.78%)

08:36
02/27/17
02/27
08:36
02/27/17
08:36
Hot Stocks
Enbridge, Spectra Energy complete merger »

Enbridge (ENB) announced…

ENB

Enbridge

$41.34

-0.37 (-0.89%)

SE

Spectra Energy

$40.68

-0.32 (-0.78%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Mar

OTIV

On Track Innovations

$1.99

-0.08 (-3.86%)

08:35
02/27/17
02/27
08:35
02/27/17
08:35
Hot Stocks
On Track Innovations announces appointment of VP of Sales »

On Track Innovations…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLK

Technology Select Sector SPDR

$52.63

0.12 (0.23%)

08:35
02/27/17
02/27
08:35
02/27/17
08:35
Technical Analysis
Technology Select Sector SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EV

Eaton Vance

$46.96

-0.24 (-0.51%)

08:35
02/27/17
02/27
08:35
02/27/17
08:35
Hot Stocks
Eaton Vance expands presence in Japan »

Eaton Vance announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SSRI

Silver Standard

$11.53

0.63 (5.78%)

08:35
02/27/17
02/27
08:35
02/27/17
08:35
Recommendations
Silver Standard analyst commentary  »

Silver Standard reproted…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WFC

Wells Fargo

$57.81

-0.68 (-1.16%)

08:35
02/27/17
02/27
08:35
02/27/17
08:35
Hot Stocks
Buffett says Wells Fargo made 'huge mistake' »

Warren Buffett said on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Apr

  • 13

    Jul

  • 12

    Oct

  • 15

    Jan

XLE

Energy Select Sector SPDR

$70.99

-0.67 (-0.93%)

08:35
02/27/17
02/27
08:35
02/27/17
08:35
Technical Analysis
Energy Select Sector SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

08:35
02/27/17
02/27
08:35
02/27/17
08:35
General news
N.Y. FX Outlook »

N.Y. FX Outlook: The…

XLY

Consumer Discretionary Sector SPDR

$86.92

0.4 (0.46%)

08:34
02/27/17
02/27
08:34
02/27/17
08:34
Technical Analysis
Consumer Discretionary Sector SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ENFC

Entegra Financial

$23.15

0.05 (0.22%)

08:34
02/27/17
02/27
08:34
02/27/17
08:34
Hot Stocks
Entegra Financial completes purchase of 2 branches in Northern Georgia »

Entegra Bank, the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLB

S&P Select Materials SPDR

$52.43

0.11 (0.21%)

08:34
02/27/17
02/27
08:34
02/27/17
08:34
Technical Analysis
S&P Select Materials SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLU

Utilities SPDR

$51.59

0.77 (1.52%)

08:33
02/27/17
02/27
08:33
02/27/17
08:33
Technical Analysis
Utilities SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMPE

Ampio

$0.80

-0.0312 (-3.75%)

08:33
02/27/17
02/27
08:33
02/27/17
08:33
Hot Stocks
Ampio: OTAT provides guidance for path to approval of Ampion »

Ampio Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CLSN

Celsion

$0.21

-0.0229 (-9.83%)

08:33
02/27/17
02/27
08:33
02/27/17
08:33
Hot Stocks
Celsion sees OVATION study to be fully enrolled, data to come in Q2 »

Celsion Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLP

Consumer Staples Sector SPDR

$55.28

0.19 (0.34%)

08:33
02/27/17
02/27
08:33
02/27/17
08:33
Technical Analysis
Consumer Staples Sector SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLV

Health Care Select Sector SPDR

$74.78

0.36 (0.48%)

08:33
02/27/17
02/27
08:33
02/27/17
08:33
Technical Analysis
Health Care Select Sector SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNCR

Synchronoss

$30.49

-0.37 (-1.20%)

08:32
02/27/17
02/27
08:32
02/27/17
08:32
Hot Stocks
Synchronoss names John Frederick as CFO, effective immediately »

Synchronoss Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.